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CLINICAL SCIENCE
Placental Structure in Preterm Birth Among HIV-Positive
Versus HIV-Negative Women in Kenya
Moses M. Obimbo, PhD,*†‡§║ Yan Zhou, MD,‡§ Michael T. McMaster, PhD,§¶
Craig R. Cohen, MD, MPH,║ Zahida Qureshi, MMED,† John Ong’ech, MMED, MPH,#
Julius A. Ogeng’o, PhD,* and Susan J. Fisher, PhD‡§**
Background: Preterm birth (PTB) is a major cause of infant
morbidity and mortality in developing countries. Recent data suggest
that in addition to Human Immunodeficiency Virus (HIV) infection,
use of antiretroviral therapy (ART) increases the risk of PTB. As the
mechanisms remain unexplored, we conducted this study to
determine whether HIV and ART were associated with placental
changes that could contribute to PTB.
Setting: We collected and evaluated placentas from 38 HIV-
positive women on ART and 43 HIV-negative women who had
preterm deliveries in Nairobi, Kenya.
Methods: Anatomical features of the placentas were examined at
gross and microscopic levels. Cases were matched for gestational
age and compared by the investigators who were blinded to maternal
HIV serostatus.
Results: Among preterm placentas, HIV infection was significantly
associated with thrombosis (P = 0.001), infarction (P = 0.032),
anomalies in cord insertion (P = 0.02), gross evidence of membrane
infection (P = 0.043), and reduced placental thickness (P = 0.010).
Overall, preterm placentas in both groups were associated with
immature villi, syncytial knotting, villitis, and deciduitis. Features of
HIV-positive versus HIV-negative placentas included significant
fibrinoid deposition with villus degeneration, syncytiotrophoblast
delamination, red blood cell adhesion, hypervascularity, and reduc-
tion in both surface area and perimeter of the terminal villi.
Conclusions: These results imply that HIV infection and/or ART
are associated with morphological changes in preterm placentas that
contribute to delivery before 37 weeks. Hypervascularity suggests
that the observed pathologies may be attributable, in part, to hypoxia.
Further research to explore potential mechanisms will help elucidate
the pathways that are involved perhaps pointing to interventions for
decreasing the risk of prematurity among HIV-positive women.
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INTRODUCTION
Preterm birth (PTB) affects approximately 10% of all
pregnancies worldwide and leads to early infant morbidity,
mortality, and chronic childhood diseases.1 Multiple factors
increase a woman’s risk of PTB, including advanced maternal
age, short intergestational interval, chronic illnesses such as
hypertension and diabetes, low maternal socioeconomic
status, and bacterial vaginosis.2,3 However, the biological
mechanisms underlying PTB remain poorly understood.4–6
In pregnancy complications, placental structure is
altered.7–11 Although Human Immunodeficiency Virus (HIV)
has been associated with adverse obstetric outcomes,12,13 the
effects of this infection on the structure of preterm placentas
remain poorly understood. Some studies have indicated alter-
ations at gross and microscopic levels, including chorioamnio-
nitis, fibrin deposition, formation of syncytial knots,
syncytiotrophoblast sloughing, villitis, villous stromal fibrosis,
infarction, abnormal villous maturation, deciduitis, and decidual
necrosis.14–18 By contrast, other investigators have failed to find
placental pathological alterations associated with HIV infection
in both term and preterm deliveries.17,19–21
Although early studies on the association of HIV and
antiretroviral therapy (ART) with prematurity have reported
conflicting results,22 more recent investigations support
a relationship.23,24 Nevertheless, the data on potential mech-
anisms by which HIV and ART may increase the risk of PTB
are limited. Thus, we conducted this study to determine
whether HIV and ART were associated with salient placental
pathologies that could contribute to an increased risk of PTB.
Identification of these changes is of critical importance to
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designing studies to explore possible biological mechanisms,
and eventually, therapeutic interventions in the setting of HIV
and ART in pregnancy aimed at reducing the risk of PTB.
MATERIAL AND METHODS
Ethical Considerations
The Kenyatta National Hospital (KNH)/University of
Nairobi Ethics and Research Committee reviewed and approved
the study protocol. A material transfer agreement was signed
between the University of Nairobi and the University of California
San Francisco, and authority to transfer material to the United
States was obtained from the KNH/University of Nairobi Ethics
and Research Committee and the Ministry of Health of Kenya.
Recruitment and Informed Consent
Trained midwives, one at KNH and the other at
Pumwani Maternity Hospital (PMH), identified subjects
who met inclusion criteria from the women who were
admitted to labor and delivery units between March and
August, 2015. Either the principal investigator (M.M.O.) or
one of the trained research assistants gave a full explanation
of the study and obtained informed consent to enroll.
Study Population
Placentas were collected from the following groups: (1) 38
HIV-positive women who received ART and had a PTB; (2) 43
HIV-negative women who delivered in the preterm period; (3) 9
HIV-positive women who received ART and delivered at term;
and (4) 11 HIV-negative women who delivered at term. Only
placentas from women of African descent aged 18–40 years with
a singleton live birth and without concomitant medical disorders or
obstetric complications such as infections, pre-eclampsia, diabetes,
cardiovascular disease, or malnutrition were included in this study.
Gestational age was determined by last normal menstrual period
and corroborated by an obstetric ultrasound before 16 weeks.
PTBs were defined as delivery at ,37 weeks of gestation, and
term births were defined as delivery $37 weeks of gestation.
Sample Collection
Clinical data and placental samples were collected at 2
sites, KNH and PMH, both located in Nairobi, Kenya. The
clinical data included maternal age, gestational age, mode of
delivery, and for those that were HIV-positive, recent CD4
counts taken within 6 months of the study period, and their
ART status (Table 1). Those on ART were asked to state
whether they were adherent to treatment or not. All HIV-
positive patients had been on ART preconception. Placentas
and the portion of the fetal membranes that were attached to the
chorionic plate were obtained aseptically immediately after
delivery and assigned a sequential study number (001-101). A
macroscopic examination was performed as described below.
Six biopsies (designated a–f) of the placentas and fetal
membranes were obtained immediately after delivery (2 central
from either side of the cord insertion and 4 from peripheral
aspects of the placenta at the 12, 3, 6, and 9 o’clock positions)
and fixed in 10% neutral buffered formalin according to
a standard protocol.25 They were then transported to Lancet
Laboratories (Nairobi) where the membranes were removed
from the placentas and made into rolls; subsequently, the rolls
and placental biopsies were dehydrated in increasing concen-
trations of alcohol (70%–100%), 1 hour per solution. Then,
they were cleared in trichloroethane (TCE) for 2 hours and
infiltrated with paraffin for 12 hours. Finally, the specimens
were embedded in fresh molten paraffin for 12 hours overnight.
Blocks, which were sectioned and stained at the University of
California San Francisco (UCSF), were subjected to micro-
scopic and morphometric analyses (see below). Stereology was
performed at the Department of Human Anatomy, University
of Nairobi.
Gross Examination
The weight of the placentas was measured by using
a Dual Display-Camry Scale (CE certified) and recorded
along with gestational age. The placentas were evaluated at
gross and microscopic levels. Grossly, the placentas were
examined for areas of infarction or thrombosis, site of cord
insertion, shape of the placenta, and color of the membranes
and chorionic plate. The length of the umbilical cord from the
proximal end (closest to the placental disc) to the distal end,
which was transected during delivery, was determined by
a flexible tape measure and recorded in centimeters. The
length of the umbilical cord segment that remained attached
to the newborn was approximately 10 cm. This value was
added to the length of the proximal segment. The cord
diameter was determined in 3 regions using a digital Vernier
TABLE 1. Comparison of Clinical Characteristics and Mode of Delivery of HIV-Positive and HIV-Negative Women Having Preterm
and Term Deliveries
Preterm
P
Term
PHIV+ (N = 38) HIV2 (N = 43) HIV+ (N = 9) HIV2 (N = 11)
Gestational age, mean, wk (range) 33.2 (28–37) 34.0 (28–37) 0.176 39 (38–41) 39 (38–41) 0.205
Maternal age at delivery, mean, yr (SD) 29.2 (3.8) 25.3 (5.5) 0.001 24.6 (5.0) 24.2 (5.3) 0.910
CD4 count (mean, SD) 379 (174)* — — 529 (213)* — —
Vaginal delivery 19 (50%) 38 (88%) ,0.001 3 (33%) 8 (73%) 0.025
Cesarean delivery 19 (50%) 5 (12%) — 6 (67%) 3 (27%) —
*PTB (n = 33); term (n = 8).
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caliper and the average was calculated (6SD). In addition, the
cords were assessed for both knotting and coiling. The
diameter of the placenta was measured, by a flexible tape,
and recorded in centimeters. The thickness at the center was
determined by piercing with a sharp rod calibrated in
millimeters. The shape of the placenta was recorded as one
of the following: discoid, annular, circular, horseshoe, or star.
Placental membrane color was described as either maroon
(normal), green-brown (meconium-stained) or yellow-gray
(infected). The information was recorded in a placental
pathology form that the Fisher laboratory routinely uses for
cases involving obstetrical complications at the University of
California San Francisco.26
Microscopic Evaluation
Five micrometer serial sections were cut using a Leitz
Wetzlar sledge microtome, floated in warm water, mounted
on glass slides, and dried in a hot air oven at 40°C overnight.
The sections were stained with Masson’s trichrome, picrosir-
ius red, or hematoxylin and eosin (H&E). H&E was used to
demonstrate the general histoarchitecture. Masson’s tri-
chrome highlighted the connective tissue components. Pic-
rosirius red stained collagen fibers. One block from each
placenta was randomly selected for further processing
through a simple random sampling technique. Slides were
examined under a Leica Automated Systems light microscope
connected to a computer and monitor. The team of inves-
tigators, who examined the slides, included a placental
biologist, 2 anatomists, and a pathologist. The investigators
were blinded to the HIV status of the mothers. The general
structural organization of the amnion, chorion, and placenta
was recorded, and the amount of fibrin deposition was noted.
Other features that were scored as described by the Fisher
group26 included villus degeneration, syncytiotrophoblast
delamination, vascularity, red blood cell adhesion to terminal
villi, intermediate mature to mature villi, syncytial knotting,
villitis, and deciduitis.
Morphometric Analyses of Terminal
Chorionic Villi
The villous structure of placentas from PTBs was
further analyzed. Five placentas from the seropositive and 5
placentas from the seronegative preterm groups were ran-
domly selected as were 2 blocks from each case, which were
subjected to morphometric analyses at 400·. Tissue sections
were examined and digital images were captured, using
a Canon color camera interfaced with an Olympus BX41
microscope, from 10 randomly selected areas per slide. Data
collection was limited to terminal villi with outlines com-
pletely within the microscopic field. Raw images were
analyzed by using Image J (Version 1.46; NIH, MD), which
enabled calculating the diameter and surface area of terminal
villi (mm2) as well as estimating the relative number of
capillaries in the stromal cores, which was scored per 10
terminal villi as either normal (2–6 capillaries), high (more
than 10 capillaries), or low (0 or 1) based on the classification
of Altshuler.27
Statistical Analysis
Gross anatomical features, histological findings, and
morphometry of preterm placentas were compared among
HIV-positive and uninfected cases. Numerical data were
analyzed by SPSS, version 20 (Chicago, IL). Mean values,
SDs, and frequency tables were compiled using descriptive
data. The independent-sample t test was used to compare the
mean values from the gross examinations by HIV serostatus.
Features of the HIV-seropositive versus HIV-seronegative
groups were compared by a x2 test. The statistical signifi-
cance of the morphometric data was determined by 1-way
analysis of variance. A P-value of ,0.05 was considered
statistically significant.
RESULTS
A total of 101 placentas were studied, 81 preterm and
20 term, with median gestational ages of 33 (range 28–37)
weeks and 39 (range 38–41) weeks, respectively. Clinical
information about these cases is summarized in Table 1. The
median maternal age for the preterm delivery group was 27
(range 18–39) years and 24 (range 18–34) years for the
mothers with term deliveries. All HIV-positive patients were
on ART with 89% having a recent CD4 count assayed within
6 months of the study period. These patients were on the first
line Ministry of Health-Kenya recommended treatment of
either stavudine or zidovudine plus lamivudine and nevir-
apine or efavirenz. We did not consider specific treatment
regimens as a variable in the analyses. At the time of this
investigation, routine viral load monitoring was not per-
formed at the 2 hospitals used for recruitment. Equal numbers
of seropositive women with PTBs delivered vaginally and by
cesarean section. In this group at term, a cesarean delivery
was more common. The seronegative mothers were more
likely to have a vaginal birth, either preterm or at term
(Table 1).
First, we examined the site of umbilical cord insertion.
Of the preterm specimens, 47/81 (58%) were marginal; 28
from seropositive and 19 from seronegative patients. Of the
remaining specimens, 33/81 (41%) had eccentric or central
cord insertions; 9 were from seropositive and 24 were from
seronegative patients (P , 0.05). One placenta from a HIV-
seropositive patient had a velamentous insertion. In term
deliveries, 9/20 (45%) showed marginal cord insertions; 7/9
(78%) were from seropositive cases and 2/9 (22%) were from
seronegative cases. Of the remaining 11 term cases with
eccentric or central cord insertions, 9/11 (82%) were sero-
negative and 2/11 (18%) were seropositive (P , 0.05).
Fetal membranes from preterm HIV-seropositive pa-
tients were evaluated and classified according to color, either
“green-brown” due to meconium staining or “yellow-gray,”
an indication of bacterial infection. In HIV-seropositive cases,
the frequency of abnormal discoloration was 26% (21/81). In
HIV-seronegative cases, the frequency was 16% (13/81). The
difference between the 2 groups was statistically significant
(P = 0.022).
Next, we examined placental vasculature. Among the
preterm delivery group, thromboses were more common (P,
0.001) in placentas from HIV-positive women (31/38; 81.6%)
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compared with HIV-negative women (18/43; 41.9%). At
term, 2/9 (22.2%) placentas from HIV-seropositive women
had thromboses, which were not detected in placentas from
HIV-seronegative women. When present, the thrombotic
lesions were more likely to be subchorionic, sometimes
involving the entire placenta. Infarctions were more common
in preterm placentas (P = 0.032) from HIV-positive (17/38;
44.7%) vs. HIV-negative women (10/43; 23.3%). The same
was true in the term birth group (6/9; 66% vs. 2/11; 18%;
P = 0.028).
With regard to placental morphometry, only placental
thickness differed significantly by maternal HIV serostatus
among the PTBs (Table 2). Cord diameter and length, as well
as placental weight and diameter, were not statistically
different between HIV-seropositive and HIV-seronegative
cases. None of these measurements were different in the 2
groups at term.
We also compared the same umbilical cord and placental
variables in the preterm and term groups according to HIV
serostatus. As expected, most of the parameters were different in
accord with their different gestational ages. In the HIV-
seropositive group, cord length and frequency of central/eccentric
insertions were not significantly different. In the HIV-
seronegative group, there was no significant difference between
cord diameter or the frequency central/eccentric insertion.
Therefore, the umbilical cord parameters were influenced less
by gestational age than the placental variables (Table 3).
Finally, histologic features of the preterm placentas
were scored in a subset of the samples (n = 22/group). The
following were significantly different in HIV-positive versus
HIV-negative placentas: fibrinoid deposition with villus
degeneration [13/22 (59%) vs. 6/22 (27%); P = 0.026],
syncytiotrophoblast delamination [10/22 (46%) vs. 2/22
(9%); P = 0.006], increased red blood cell adhesion to
terminal villi [11/22 (50%) vs. 2/22 (9%); P = 0.003], and
increased number of capillaries [7/22 (32%) vs. 0/22 (0%); P
, 0.05]. Other histologic features were not different between
the preterm groups including intermediate mature to mature
villi [18/22 (82%) vs. 16/22 (73%); P = 0.355]; syncytial
knotting [14/22 (64%) vs. 16/22 (73%); P = 0.973]; villitis
(11/22 (50%) vs. 9/22 (41%); P = 0.403]; and deciduitis [13/
22 (59%) vs. 13/22 (59%); P = 0.702].
Figure 1 illustrates the most prominent histologic
features of term and preterm placentas from HIV-positive
versus HIV-negative women. The sections were stained with
either H&E (A–D and H) or Masson’s trichrome (E–G).
Placentas from a normal HIV-negative pregnancy at term
showed the typical microscopic features of floating and stem
villi, including syncytial knots (Fig. 1A). Little fibrin
deposition was observed. Term placentas from HIV-positive
TABLE 2. Comparison of the Morphometric Parameters of Placentas From Preterm and Term Deliveries in HIV-Infected and
Uninfected Women
Variable
Preterm
P
Term
PHIV+ (n = 38) HIV2 (n = 43) HIV+ (n = 9) HIV2 (n = 11)
Cord diameter (mean, mm) 9.66 10.53 0.054 12.11 11.45 0.769
Cord length (mean, cm) 54.74 54.37 0.784 57.89 57.55 0.708
Cord insertion
Central/eccentric 9 24 0.006 2 9 0.021
Marginal 28 19 — 7 2 —
Velamentous 1 — — — — —
Placental weight (mean, g) 509.55 524.12 0.439 614.22 622.82 0.522
Placenta greatest diameter (mean, cm) 15.21 16 0.091 17.22 17.82 0.14
Placental thickness (mean, cm) 1.974 2.226 *0.010 2.711 2.936 0.911
*Placentas from HIV-infected women with preterm deliveries were significantly thinner compared with the counterparts.
TABLE 3. Comparison of Placental Morphometric Parameters (Table 2) by Serostatus
Variable
HIV-Positive
P
HIV-Negative
PPreterm (n = 38) Term (n = 9) Preterm (n = 43) Term (n = 11)
Cord diameter (mean, mm) 9.66 12.11 ,0.001 10.53 11.45 0.23
Cord length (mean, cm) 54.74 57.89 0.082 54.37 57.55 0.034
Cord insertion
Central/eccentric 9 2 0.894 24 9 0.114
Marginal 28 7 — 19 2 —
Velamentous 1 — — — — —
Placental weight (mean, g) 509.55 614.22 ,0.001 524.12 622.82 ,0.001
Placenta greatest diameter (mean, cm) 15.21 17.22 ,0.001 16 17.82 ,0.001
Placental thickness (mean, cm) 1.974 2.711 ,0.001 2.226 2.936 ,0.001
Bold values indicates statistical significance.
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women on ART had similar histologic features except for
frequent fibrin deposits (Fig. 1B). Microscopic examination
of preterm placentas from HIV-negative women showed
numerous intermediate mature to mature villi; fibrin deposits
were not observed (Fig. 1C). Preterm placentas from HIV-
positive women on ART had extensive fibrin deposits in the
perivillous and intervillous regions sometimes obliterating the
structure of floating and stem villi (Figs. 1D–H).
Placentas such as the one shown in Figure 2A were
examined at higher magnification (B and C), which
revealed syncytiotrophoblast delamination and prominent
perivillous eosinophilic fibrin, respectively. In some areas,
red blood cell adhesion to the villus surfaces was also
evident (Fig. 2D). The terminal villi showed an increase in
capillary density and a decrease in villus surface area
(Figs. 2E and F).
FIGURE 1. Histology of term and
preterm placentas from HIV-positive
women on antiretroviral treatment
(ART) versus HIV-negative women.
The placental biopsies were pre-
pared for paraffin wax embedding,
sectioned and stained with either
hematoxylin and eosin (A–D and H)
or Masson’s trichrome (E–G) stains.
A, Placenta from a normal HIV-neg-
ative pregnancy at term. Note the
organization of the floating villi,
stem villus, and the syncytial knots.
Fibrin material is scant in this sec-
tion. B, Placenta of a term preg-
nancy from a HIV-positive woman
on ART. Numerous fibrin deposits
(Fd) were evident as were syncytial
knots, normal in a term placenta. C,
Preterm placenta from a HIV-nega-
tive woman. The intervillous spaces,
which were clear, contained inter-
mediate mature and mature villi.
D–H, Preterm placentas from HIV-
positive women on ART had obvious
fibrin deposition in the perivillous
and intervillous regions sometimes
obliterating the structure of floating
and stem villi. Asterisks in panels G
and H show areas of intervillous
fibrin deposition. A, 39 weeks; (B) 39
weeks; (C) 33 weeks; (D) 34 weeks;
(E) 35 weeks; (F) 34 weeks; (G) 33
weeks; and (H) 30 weeks of gesta-
tion. Scale bars, 200 mm.
Obimbo et al J Acquir Immune Defic Syndr  Volume 80, Number 1, January 1, 2019
98 | www.jaids.com Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
Compared with HIV-seronegative preterm placentas,
those from seropositive women who gave birth during the
preterm period had significantly smaller villous areas (2650–
3150 mm2/random field vs. 2900–3450 mm2; P , 0.05). The
preterm placentas from seropositive women also exhibited
a reduction in villus perimeter (mean of 186 vs. 244 mm; P ,
0.005). The villus surface area (HIV-negative, 2450–
2700 mm2/random field versus HIV-positive, 2600–
2850 mm2; P = 0.22) and perimeter (HIV-negative, 185 mm
vs. HIV-positive, 181 mm) from term placentas did not vary
according to serostatus.
DISCUSSION
In this study of the effects of HIV infection and ART on
the preterm placenta, we found that the samples from the
HIV-positive women had unique gross anatomical and
histological findings indicative of placental damage. Grossly,
placentas from the HIV-positive women had an unusually
high rate of marginal cord insertion, thrombosis, infarction,
and were thinner. Because all the women in this group
received ART, it was not possible to determine whether the
observed placental pathologies were associated with HIV
infection, treatment, or both. Of relevance, some HIV-
associated lesions such as chorioamnionitis, deciduitis, pla-
cental membrane inflammation, and funisitis have previously
been described.28 With the World Health Organization
(WHO) 2013 “Option B+” policy, all HIV-positive women
of reproductive age are either on ART preconception or are
initiated immediately if the diagnosis is made during
pregnancy.29 With ART adherence, viral suppression may
be achieved, and it is therefore plausible to suggest that most
of the features observed in the placentas of HIV-positive
women are associated more with ART than the HIV infection.
As to specific features, the high frequency of marginal
cord insertions in HIV-positive women is unusual. Pre-
viously, this anatomical feature has been associated with
poor fetal outcomes including PTB and intrauterine growth
restriction because of chorionic regression and impairment of
placental function.30,31 The exact mechanism of marginal
FIGURE 2. Microstructural changes
in the terminal villi of preterm pla-
centas from HIV-positive women on
antiretroviral therapy (ART). The
sections were stained using hema-
toxylin and eosin (A–C, E and F) or
Masson’s trichrome (D). A, General
architecture of the floating villi with
their syncytiotrophoblast (STB) cov-
erings (arrows; scale bar, 200 mm). B
and C, Higher magnification of dif-
ferent fields from the same placenta
showing regions of STB delamina-
tion associated with the terminal villi
(asterisks). C, Areas of perivillous,
eosinophilic fibrin deposits (Fd) were
evident (scale bar 50 mm). D, Red
blood cell adherence to the villi (as-
terisks; scale bar 50 mm). E and F,
Higher number of capillaries (Cp) in
the terminal villi with significant in-
creases in the intervening inter-
villous spaces (IVS) [scale bars: (E)
150 mm; (F) 200 mm]. A, 35 weeks;
(B) 35 weeks; (C) 35 weeks; (D) 32
weeks; (E) 33 weeks; and (F) 31
weeks of gestation.
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cord insertion is unknown. This type of insertion may result
from a process known as trophotropism in which the chorion
frondosum of the early placenta migrates to a more well-
vascularized zone of the uterine wall as pregnancy advan-
ces.32 This feature was observed in both HIV-positive term
and preterm placentas with almost equal frequency and may
be related to either the HIV-positive serostatus or ART.
Further work is needed to decipher the potential mechanisms
involved in this process. There were nearly equal numbers of
HIV-positive and -negative women with PTB who had fetal
membranes with features of chorioamnionitis. However, we
did not assess other specific forms of infection in this study.
The presence of placental infection increases by 2-fold the
risk of PTB.33–35 The higher incidence of meconium staining
of preterm placental membranes in HIV-positive mothers may
also signify fetal distress because of poor placental function
including uteroplacental insufficiency.
Our finding of increased placental thrombosis and
infarction in HIV-positive mothers is in accord with previous
reports36–38 and at variance with others.39,40 These vascular
pathologies have been attributed to HIV-associated upregu-
lation of the extrinsic coagulation pathway with fibrinoid
deposition.41,42 As to mechanism, upregulation of the coag-
ulation cascade leads to increased thrombin generation,43
which triggers fibrin generation and platelet aggregation.44,45
The consequences could include a predisposition to preterm
rupture of membranes, PTB, intrauterine growth restriction,
pre-eclampsia, and fetal demise.46
We also noted that the placentas of HIV-positive
mothers were thinner than those of their uninfected counter-
parts. This was at odds with a report that found no difference
in placental dimensions with HIV serostatus.21 By contrast,
cytomegalovirus infection is associated with an increase in
placental thickness, but the mechanism is not well-under-
stood.47 Several other anatomical features did not differ
between the placentas of the HIV-positive and uninfected
groups. In addition, the mean weights of term and preterm
placentas fell within the standard percentiles for their
gestational ages.48 This was in contrast to previous reports
that the placentas of HIV-positive mothers were smaller and
weighed less compared with their uninfected counter-
parts.49,50 These findings suggest that ART may preserve
placental growth and, ultimately, weight.
As to the histological analyses, villitis and deciduitis
were common in placentas from HIV-positive and uninfected
mothers. These pathological features are almost always the
result of ascending infection, which may lead to necrosis of
the terminal villi and decidua.51 Their presence may signify
undesirable pregnancy outcomes including PTB. By contrast,
lesions that were unique to the placentas of mothers with PTB
and HIV infection included fibrinoid deposition with villus
degeneration, syncytiotrophoblast delamination, increased red
cell adhesion, and hypervascularity of the terminal villi.
Although a normal placenta may have a small amount of
perivillous fibrinoid due to eddying of the blood, significant
fibrin deposition occurs secondary to clotting of maternal
blood in the intervillous space.52 As a result, the entrapped
chorionic villi atrophy.53 The underlying mechanism of this
process remains poorly understood but could be related to the
aforementioned HIV-induced immunological activation of the
extrinsic clotting pathway.54,55 The observed destruction of
the syncytiotrophoblast layer in placentas of these patients
could be through HIV-induced, cytokine-mediated inflamma-
tory responses and may imply a compromised feto-maternal
interface with attendant risks such as PTB.56,57
Some of the pathological features that we observed
were specific to the terminal villi. Erythrocyte adhesion to this
region has been described in placental malaria and in the
placentas of growth-restricted fetuses.58 This process, which
may be initiated by STB destruction or apoptosis,59 leads to
local immune complex formation, which may further damage
STBs, initiating a vicious cycle that ultimately damages the
placenta.60
Hypervascularity of terminal villi, defined as excessive
numbers of capillaries,27 is associated with chronic hypoxia and
encountered in other obstetric complications.61–63 Recent
studies in mice exposed to combined ART throughout
pregnancy demonstrated enhanced branching of the placental
vasculature with increased numbers of small diameter vessels.64
This may indicate that maternal ART promotes this process or
new capillary formation. Finally, the reduced villus surface area
and perimeter in placentas of HIV-positive mothers with PTB
was in keeping with other reports.65,66 This manifestation has
been attributed to new branching of the intermediate villi,
giving rise to multiple terminal villi, a potential compensatory
mechanism for a dysfunctional placenta.67,68
In conclusion, these results imply that maternal HIV
and ART are associated with salient morphological changes
in preterm placentas that could contribute to delivery before
37 weeks of gestation. Given the observed hypervascularity,
the attendant pathologies may be attributable, in part, to
hypoxia. Further research to explore potential mechanisms
will help elucidate the pathways that are involved perhaps
pointing to interventions for decreasing the risk of PTB
among HIV-positive women.
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